Developing a new treatment for acute pancreatitis in dogs and humans
One Health Advancement of RABI-767 for the Management of Acute Pancreatitis
['FUNDING_SBIR_2'] · LAMASSU PHARMA INC. · NIH-10921425
This study is exploring a new treatment for acute pancreatitis, a serious condition that currently has no good options, by testing a promising compound called RABI-767 in dogs to see how well it works and is tolerated, which will help us develop better therapies for both dogs and people in the future.
Quick facts
| Phase | ['FUNDING_SBIR_2'] |
|---|---|
| Study type | Nih_funding |
| Sex | All |
| Sponsor | LAMASSU PHARMA INC. (nih funded) |
| Locations | 1 site (Durham, UNITED STATES) |
| Trial ID | NIH-10921425 on ClinicalTrials.gov |
What this research studies
This research focuses on creating a novel therapy for acute pancreatitis, a serious condition with no effective treatments available. The approach is based on understanding how fat breakdown and toxicity contribute to the severity of the disease. The research involves testing a lead compound, RABI-767, in canine models to evaluate its effectiveness and safety, which will also inform future human clinical trials. The study aims to optimize dosing schedules to improve treatment outcomes for both dogs and humans suffering from this condition.
Who could benefit from this research
Good fit: Ideal candidates for this research include dogs diagnosed with spontaneous acute pancreatitis and potentially humans with the same condition in future trials.
Not a fit: Patients with chronic pancreatitis or those not diagnosed with acute pancreatitis may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to a new effective treatment for acute pancreatitis, significantly improving patient outcomes.
How similar studies have performed: Previous research has shown promise in using similar therapeutic approaches for treating acute pancreatitis, indicating potential for success in this novel treatment.
Where this research is happening
Durham, UNITED STATES
- LAMASSU PHARMA INC. — Durham, UNITED STATES (ACTIVE)
Researchers
- Principal investigator: HANNA, GABI — LAMASSU PHARMA INC.
- Study coordinator: HANNA, GABI
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.